Conivaptan - PharmaKB

Conivaptan

Vaprisol (conivaptan) is a small molecule pharmaceutical. Conivaptan was first approved as Vaprisol on 2005-12-29. It is used to treat hyponatremia in the USA. The pharmaceutical is active against vasopressin V2 receptor and vasopressin V1a receptor.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
nutritional and metabolic diseases	D009750

Trade Name

FDA

EMA

Vaprisol (discontinued: Vaprisol)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Conivaptan hydrochloride

Tradename	Company	Number	Date	Products
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	Cumberland Pharmaceuticals	N-021697 RX	2008-10-08	1 products, RLD, RS

Show 1 discontinued

Labels

FDA

EMA

No data

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
hyponatremia	HP_0002902	D007010	E87.1

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

C: Cardiovascular system drugs

— C03: Diuretics

— C03X: Other diuretics in atc

— C03XA: Vasopressin antagonists, diuretics

— C03XA02: Conivaptan

HCPCS

Code	Description
C9488	Injection, conivaptan hydrochloride, 1 mg

Clinical

Clinical Trials

21 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hyponatremia	D007010	HP_0002902	E87.1	2	—	7	2	—	11
Heart failure	D006333	HP_0001635	I50	—	1	1	2	2	6
Hypovolemia	D020896	HP_0011106	E86	—	—	—	1	—	1

Indications Phases 3

No data

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Stroke	D020521	EFO_0000712	I63.9	1	1	—	—	—	2
Edema	D004487	HP_0000969	R60.9	1	1	—	—	—	2
Brain edema	D001929	EFO_1000845	G93.6	1	1	—	—	—	2
Liver cirrhosis	D008103	EFO_0001422	K74.0	—	1	—	—	—	1
Fibrosis	D005355	—	—	—	1	—	—	—	1

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Liver diseases	D008107	HP_0002910	K70-K77	2	—	—	—	—	2
Hemorrhage	D006470	MP_0001914	R58	1	—	—	—	—	1
Cerebral hemorrhage	D002543	—	—	1	—	—	—	—	1
Wounds and injuries	D014947	—	T14.8	1	—	—	—	—	1
Traumatic brain injuries	D000070642	—	S06	1	—	—	—	—	1
Brain injuries	D001930	—	S06.9	1	—	—	—	—	1
Kidney diseases	D007674	EFO_0003086	N08	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hypertension	D006973	EFO_0000537	I10	—	—	—	—	1	1
Pulmonary hypertension	D006976	EFO_0001361	I27.20	—	—	—	—	1	1
Pulmonary arterial hypertension	D000081029	—	—	—	—	—	—	1	1

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Conivaptan
INN	conivaptan
Description	Conivaptan is the amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). It has a role as a vasopressin receptor antagonist and an aquaretic.
Classification	Small molecule
Drug class	aptamers, classical and mirror; vasopressin receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2